{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T22:27:07.918203+00:00","company":{"ticker":"ABT","cik":1800,"company_name":"ABBOTT LABORATORIES"},"pagination":{"limit":100,"returned":10,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"governance_change","fact_key":"21c9f50a61d20d64472881a01e00a5a49d09cb09","cik":1800,"ticker":"ABT","company_name":"ABBOTT LABORATORIES","filed_at":"2026-04-27T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2026-04-24","item_codes_triggered":["5.03"],"summary_text":"Board size increased from twelve to thirteen directors"},"claim":"ABBOTT LABORATORIES: Board size increased from twelve to thirteen directors (effective 2026-04-24).","evidence_excerpt":"On April 24, 2026, Abbott’s Board of Directors amended the first sentence of Article III, Section 2 of Abbott’s by-laws to provide that Abbott’s Board of Directors shall consist of thirteen persons, effective April 24, 2026.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-049434","anchor_url":"https://secwatch.observer/filing/0001104659-26-049434#claim-21c9f50a61d20d64472881a01e00a5a49d09cb09","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1800/000110465926049434/0001104659-26-049434-index.htm"},{"fact_type":"earnings_release","fact_key":"3c1b68443e4c7de69c282c93fbaff1e08f7aa7e6","cik":1800,"ticker":"ABT","company_name":"ABBOTT LABORATORIES","filed_at":"2026-04-16T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter ended March 31, 2026","report_date":"2026-04-16","result_type":"reported_results","revenue_text":null},"claim":"ABBOTT LABORATORIES updated its first quarter ended March 31, 2026 guidance (reaffirmed).","evidence_excerpt":"On April 16, 2026, Abbott Laboratories announced its results of operations for the first quarter 2026.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-26-025365","anchor_url":"https://secwatch.observer/filing/0001628280-26-025365#claim-3c1b68443e4c7de69c282c93fbaff1e08f7aa7e6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026025365/0001628280-26-025365-index.htm"},{"fact_type":"debt_financing","fact_key":"52fc7ee8ff3d92cccaa0892323e1b42f40af9c61","cik":1800,"ticker":"ABT","company_name":"ABBOTT LABORATORIES","filed_at":"2026-03-09T23:59:59+00:00","payload":{"counterparty":"Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC","effective_date":"2026-03-09","event":"incurrence","instrument_type":"senior_notes","interest_rate_text":"Floating Rate Notes due 2029, 3.700% Notes due 2029, 4.000% Notes due 2031, 4.30","item_codes_triggered":["2.03"],"maturity_text":"2029, 2029, 2031, 2033, 2036, 2038, 2056 and 2066","principal_text":"$20,000,000,000 aggregate principal amount"},"claim":"ABBOTT LABORATORIES incurred senior notes of $20,000,000,000 aggregate principal amount with Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC at Floating Rate Notes due 2029, 3.700% Notes due 2029, 4.000% Notes due 2031, 4.30 maturing 2029, 2029, 2031, 2033, 2036, 2038, 2056 and 2066.","evidence_excerpt":"On March 9, 2026, Abbott Laboratories (“Abbott”) completed the public offering and issuance of $20,000,000,000 aggregate principal amount of senior notes","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-025240","anchor_url":"https://secwatch.observer/filing/0001104659-26-025240#claim-52fc7ee8ff3d92cccaa0892323e1b42f40af9c61","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1800/000110465926025240/0001104659-26-025240-index.htm"},{"fact_type":"material_agreement","fact_key":"ff7d9f4f68de024e8ac32e689b1d43bf1d451776","cik":1800,"ticker":"ABT","company_name":"ABBOTT LABORATORIES","filed_at":"2026-03-09T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Pricing Agreement","agreement_type":"underwriting","counterparty":"Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC","effective_date":"2026-02-23","item_codes_triggered":["1.01"],"value_text":"$20,000,000,000 aggregate principal amount"},"claim":"ABBOTT LABORATORIES entered into Pricing Agreement with Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC valued at $20,000,000,000 aggregate principal amount (effective 2026-02-23).","evidence_excerpt":"The Notes were sold pursuant to a pricing agreement, dated February 23, 2026 (the “Pricing Agreement”), by and among Abbott, Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC, for themselves and as representatives of the several other underwriters named therein.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-025240","anchor_url":"https://secwatch.observer/filing/0001104659-26-025240#claim-ff7d9f4f68de024e8ac32e689b1d43bf1d451776","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1800/000110465926025240/0001104659-26-025240-index.htm"},{"fact_type":"material_agreement","fact_key":"9ab9c24e25e11ef0de341d49ab1fe4c3cf0bb19b","cik":1800,"ticker":"ABT","company_name":"ABBOTT LABORATORIES","filed_at":"2026-02-26T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Pricing Agreement","agreement_type":"underwriting","counterparty":"Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC","effective_date":"2026-02-23","item_codes_triggered":["1.01"],"value_text":"$20,000,000,000 aggregate principal amount"},"claim":"ABBOTT LABORATORIES entered into Pricing Agreement with Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC valued at $20,000,000,000 aggregate principal amount (effective 2026-02-23).","evidence_excerpt":"On February 23, 2026, Abbott Laboratories (“Abbott”) entered into a pricing agreement (the “Pricing Agreement”), dated February 23, 2026, by and among Abbott, Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC, for themselves and as representatives of the several other underwriters named therein (the “Underwriters”), pursuant to which Abbott agreed to issue and sell $20,000,000,000 aggregate principal amount of senior notes","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-020509","anchor_url":"https://secwatch.observer/filing/0001104659-26-020509#claim-9ab9c24e25e11ef0de341d49ab1fe4c3cf0bb19b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1800/000110465926020509/0001104659-26-020509-index.htm"},{"fact_type":"governance_change","fact_key":"620a55efc493d678873bdc82a6927ca0540a7909","cik":1800,"ticker":"ABT","company_name":"ABBOTT LABORATORIES","filed_at":"2026-02-20T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2026-04-24","item_codes_triggered":["5.03"],"summary_text":"Board reduced from thirteen to twelve members, effective April 24, 2026."},"claim":"ABBOTT LABORATORIES: Board reduced from thirteen to twelve members, effective April 24, 2026 (effective 2026-04-24).","evidence_excerpt":"On February 20, 2026, Abbott’s Board of Directors amended the first sentence of Article III, Section 2 of Abbott’s By-Laws to provide that Abbott’s Board of Directors shall consist of twelve persons, effective April 24, 2026.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-018167","anchor_url":"https://secwatch.observer/filing/0001104659-26-018167#claim-620a55efc493d678873bdc82a6927ca0540a7909","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1800/000110465926018167/0001104659-26-018167-index.htm"},{"fact_type":"governance_change","fact_key":"603670d58a5f30b38502bf0444fa74d7eb678c1a","cik":1800,"ticker":"ABT","company_name":"ABBOTT LABORATORIES","filed_at":"2025-12-12T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2025-12-12","item_codes_triggered":["5.03"],"summary_text":"Increased board size from twelve to thirteen directors by amending Article III, Section 2 of the by-laws."},"claim":"ABBOTT LABORATORIES: Increased board size from twelve to thirteen directors by amending Article III, Section 2 of the by-laws (effective 2025-12-12).","evidence_excerpt":"On December 12, 2025, Abbott’s Board of Directors amended the first sentence of Article III, Section 2 of Abbott’s by-laws to provide that Abbott’s Board of Directors shall consist of thirteen persons, effective as of December 12, 2025.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-25-120657","anchor_url":"https://secwatch.observer/filing/0001104659-25-120657#claim-603670d58a5f30b38502bf0444fa74d7eb678c1a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1800/000110465925120657/0001104659-25-120657-index.htm"},{"fact_type":"executive_change","fact_key":"f67e5cb974","cik":1800,"ticker":"ABT","company_name":"ABBOTT LABORATORIES","filed_at":"2025-05-01T23:59:59+00:00","payload":{"action":"retire","action_category":"departure","departure_tone":"retirement","effective_date":null,"interim":false,"role":"Executive Vice President, General Counsel and Secretary","role_category":"general_counsel","successor_name":null,"successor_named":false},"claim":"Hubert L. Allen departed as Executive Vice President, General Counsel and Secretary at ABBOTT LABORATORIES.","evidence_excerpt":"On April 25, 2025, Hubert L. Allen, Executive Vice President, General Counsel and Secretary, informed Abbott Laboratories that he plans to retire from the company after a period of transition.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-25-043508","anchor_url":"https://secwatch.observer/filing/0001104659-25-043508#claim-f67e5cb974","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1800/000110465925043508/0001104659-25-043508-index.htm"},{"fact_type":"executive_change","fact_key":"58dedb079e","cik":1800,"ticker":"ABT","company_name":"ABBOTT LABORATORIES","filed_at":"2024-05-01T23:59:59+00:00","payload":{"action":"plans to retire","action_category":"departure","departure_tone":"retirement","effective_date":"2024-07-01","interim":false,"role":"Executive Vice President, Finance","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Robert E. Funck, Jr. departed as Executive Vice President, Finance at ABBOTT LABORATORIES.","evidence_excerpt":"Robert E. Funck, Jr., Executive Vice President, Finance, informed Abbott Laboratories that he plans to retire from the company after 36 years of service, effective July 1, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-055724","anchor_url":"https://secwatch.observer/filing/0001104659-24-055724#claim-58dedb079e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1800/000110465924055724/0001104659-24-055724-index.htm"},{"fact_type":"earnings_release","fact_key":"363ebc874444fa0e298452202d8bc7a2323e828c","cik":1800,"ticker":"ABT","company_name":"ABBOTT LABORATORIES","filed_at":"2024-04-17T23:59:59+00:00","payload":{"eps_text":"$0.70","guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the first quarter ended March 31, 2024","report_date":"2024-04-17","result_type":"reported_results","revenue_text":"$10.0 billion"},"claim":"ABBOTT LABORATORIES reported the first quarter ended March 31, 2024 results: revenue $10.0 billion, EPS $0.70. Guidance raised.","evidence_excerpt":"Abbott Reports First-Quarter 2024 Results and Raises Midpoint of Full-Year Guidance Ranges – Sales of $10.0 billion driven by strong underlying base business performance – Reported sales increased 2.2 percent, which includes the impact from the anticipated decline in COVID-19 testing-related sales versus prior year – Organic sales growth for underlying base business of 10.8 percent, which represents the fifth consecutive quarter of double-digit growth  1 ABBOTT PARK, Ill., April 17, 2024 — Abbott today announced financial results for the first quarter ended March 31, 2024. • First-quarter GAAP diluted EPS of $0.70 and adjusted diluted EPS of $0.98, which excludes specified items.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-24-016497","anchor_url":"https://secwatch.observer/filing/0001628280-24-016497#claim-363ebc874444fa0e298452202d8bc7a2323e828c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828024016497/0001628280-24-016497-index.htm"}]}